Thus studying the impact of risk variants like TREM2 or ApoE4 in vivo at the stage of DAMs might not provide us full insights of their contribution to early, preclinical stages of AD pathology, i.e. before plaques start to occur. This evidence concerns the gene APOE and Alzheimer disease.